Epigenomics offers comprehensive Biomarker Services based on its leading DNA methylation technology portfolio. DNA methylation biomarkers support drug development at all stages - by helping to predict drug response and disease prognosis or to monitor treatment with a given drug.

Epigenomics' DNA Methylation Biomarker Services include:

• Biomarker Discovery - Epigenomics offers Differential Methylation Hybridization (DMH) - a genome-wide DNA methylation profiling technology uniquely designed for rapid and efficient discovery of DNA methylation biomarker candidates for various clinical applications. Now available! - Mouse DMH microarry available as of July 2007!
• Biomarker Selection - Epigenomics offers Bisulfite Sequencing for the DNA methylation analysis of selected candidate genes (e.g. from Biomarker Discovery) in a wide variety of sample types.
• Clinical Proof-of-Concept - Epigenomics offers proprietary DNA methylation amplification technologies for the development of highly quantitative and sensitive DNA methylation assays for proof-of-concept in clinical sample collections.  
• IVD Test Development - Epigenomics offers IVD test development for DNA methylation biomarkers on its in-house diagnostic platform or other platforms suitable for regulatory approval. 

Interested parties may access Epigenomics' Biomarker Services through selected fee for service packages, IVD test development partnerships and licensing arrangements.

Please contact us to find out how Epigenomics can best support your biomarker needs.